vs
Side-by-side financial comparison of NEW JERSEY RESOURCES CORP (NJR) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
NEW JERSEY RESOURCES CORP is the larger business by last-quarter revenue ($939.4M vs $619.8M, roughly 1.5× QuidelOrtho Corp). NEW JERSEY RESOURCES CORP runs the higher net margin — 23.3% vs -14.8%, a 38.1% gap on every dollar of revenue. On growth, QuidelOrtho Corp posted the faster year-over-year revenue change (-10.5% vs -33.0%). Over the past eight quarters, NEW JERSEY RESOURCES CORP's revenue compounded faster (111.6% CAGR vs -6.6%).
New Jersey Resources is an energy services holding company based in Wall Township, New Jersey. It is a Fortune 1000 company, and a member of the Forbes Platinum 400. New Jersey Natural Gas is its principal subsidiary.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
NJR vs QDEL — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $939.4M | $619.8M |
| Net Profit | $218.9M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | 32.0% | — |
| Net Margin | 23.3% | -14.8% |
| Revenue YoY | -33.0% | -10.5% |
| Net Profit YoY | 7.2% | — |
| EPS (diluted) | $2.16 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $939.4M | $619.8M | ||
| Q4 25 | $440.9M | — | ||
| Q3 25 | $188.3M | $699.9M | ||
| Q2 25 | $234.8M | $613.9M | ||
| Q1 25 | $569.2M | $692.8M | ||
| Q4 24 | $359.0M | $707.8M | ||
| Q3 24 | $265.7M | $727.1M | ||
| Q2 24 | $209.9M | $637.0M |
| Q1 26 | $218.9M | $-91.8M | ||
| Q4 25 | $122.5M | — | ||
| Q3 25 | $15.1M | $-733.0M | ||
| Q2 25 | $-15.1M | $-255.4M | ||
| Q1 25 | $204.3M | $-12.7M | ||
| Q4 24 | $131.3M | $-178.4M | ||
| Q3 24 | $91.1M | $-19.9M | ||
| Q2 24 | $-11.6M | $-147.7M |
| Q1 26 | 32.0% | — | ||
| Q4 25 | 40.6% | — | ||
| Q3 25 | 21.5% | -100.7% | ||
| Q2 25 | -0.5% | -29.4% | ||
| Q1 25 | 49.2% | 4.7% | ||
| Q4 24 | 52.8% | -14.2% | ||
| Q3 24 | 55.0% | 2.1% | ||
| Q2 24 | 2.8% | -18.4% |
| Q1 26 | 23.3% | -14.8% | ||
| Q4 25 | 27.8% | — | ||
| Q3 25 | 8.0% | -104.7% | ||
| Q2 25 | -6.4% | -41.6% | ||
| Q1 25 | 35.9% | -1.8% | ||
| Q4 24 | 36.6% | -25.2% | ||
| Q3 24 | 34.3% | -2.7% | ||
| Q2 24 | -5.5% | -23.2% |
| Q1 26 | $2.16 | $-1.35 | ||
| Q4 25 | $1.21 | — | ||
| Q3 25 | $0.15 | $-10.78 | ||
| Q2 25 | $-0.15 | $-3.77 | ||
| Q1 25 | $2.02 | $-0.19 | ||
| Q4 24 | $1.31 | $-2.54 | ||
| Q3 24 | $0.91 | $-0.30 | ||
| Q2 24 | $-0.12 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | — | $1.9B |
| Total Assets | — | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | $2.4M | — | ||
| Q3 25 | $591.0K | $98.1M | ||
| Q2 25 | $931.0K | $151.7M | ||
| Q1 25 | $83.7M | $127.1M | ||
| Q4 24 | $1.9M | $98.3M | ||
| Q3 24 | $1.0M | $143.7M | ||
| Q2 24 | $22.4M | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | $3.3B | — | ||
| Q3 25 | $3.3B | $2.5B | ||
| Q2 25 | $3.0B | $2.1B | ||
| Q1 25 | $3.0B | $2.1B | ||
| Q4 24 | $3.0B | $2.1B | ||
| Q3 24 | $2.9B | $2.2B | ||
| Q2 24 | $2.8B | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | $2.0B | ||
| Q2 25 | $2.4B | $2.8B | ||
| Q1 25 | $2.5B | $3.0B | ||
| Q4 24 | $2.3B | $3.0B | ||
| Q3 24 | $2.2B | $3.2B | ||
| Q2 24 | $2.1B | $3.2B |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $7.9B | — | ||
| Q3 25 | $7.6B | $5.7B | ||
| Q2 25 | $7.3B | $6.4B | ||
| Q1 25 | $7.3B | $6.5B | ||
| Q4 24 | $7.2B | $6.4B | ||
| Q3 24 | $7.0B | $6.8B | ||
| Q2 24 | $6.8B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | 1.32× | — | ||
| Q3 25 | 1.36× | 1.23× | ||
| Q2 25 | 1.25× | 0.74× | ||
| Q1 25 | 1.20× | 0.70× | ||
| Q4 24 | 1.29× | 0.72× | ||
| Q3 24 | 1.31× | 0.68× | ||
| Q2 24 | 1.30× | 0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NJR
| Utility | $640.9M | 68% |
| Nonutility | $298.5M | 32% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
